Next Article in Journal
Assessing the Linkage between Exposure to Violence and Victimization, Coping, and Adjustment among Urban Youth: Findings from a Research Study on Adolescents
Next Article in Special Issue
Toolkit for Population Health Initiatives Around the Globe Related to Collaborative Comprehensive Medication Management for Children and Youth
Previous Article in Journal
Status of Pediatric Cardiac Care in Developing Countries
Previous Article in Special Issue
Where are the Ambulatory Care Pediatric Pharmacists?
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Children 2019, 6(2), 35; https://doi.org/10.3390/children6020035

Description of an Innovative Pediatric Individualized Therapeutics Clinic: Working toward Precision Drug Therapy

Division of Clinical Pharmacology/Medical Toxicology and Therapeutic Innovation, Children’s Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA
*
Author to whom correspondence should be addressed.
Received: 23 January 2019 / Revised: 15 February 2019 / Accepted: 19 February 2019 / Published: 25 February 2019
  |  
PDF [966 KB, uploaded 28 February 2019]
  |  

Abstract

The GOLDILOKs® (Genomic and Ontogeny-Linked Dose Individualization and cLinical Optimization for KidS) Clinic aims to provide families and physicians with data to make more informed decisions with regard to pharmacological therapy by using innovative therapy and genomic technologies. The objectives are two-fold: (1) To describe the utility of the GOLDILOKs® Clinic to referring prescribers by evaluating the type of referrals made to the GOLDILOKs® Clinic and (2) to assess the most often utilized technologies (e.g., genotyping) completed to formulate therapy recommendations. Patient data from July 2010 to June 2016 was retrospectively reviewed following Institutional Review Board (IRB) approval. The GOLDILOKs® Clinic evaluated 306 patients and had increases in annual referrals from 14 in 2010–2011 to 84 in 2016–2017. The children that were referred were predominately Caucasian (82%) and male (59%) with an average age of 12.4 ± 5.9 years. Subspecialty versus primary care referrals accounted for 82% and 18% of referrals, respectively. Adverse drug reactions (n = 166) and poor medication response (n = 179) were the major reasons for referral. However, it must be noted that patients could have multiple reasons for referral. Pharmacogenetic results were extensively used to provide guidance for future therapy in patients with medication-related problems. Genotyping of drug metabolizing enzymes and drug target receptors was performed in 221 patients (72.2%). Recommendations were fully accepted by 63% and partially accepted by 22% of internal provider referrals. View Full-Text
Keywords: pharmacogenetics; personalized medicine; pediatrics; multidisciplinary clinic; adverse drug reaction pharmacogenetics; personalized medicine; pediatrics; multidisciplinary clinic; adverse drug reaction
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sandritter, T.L.; Dinh, J.C.; Wagner, J.A.; Lowry, J.A. Description of an Innovative Pediatric Individualized Therapeutics Clinic: Working toward Precision Drug Therapy. Children 2019, 6, 35.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Children EISSN 2227-9067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top